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Abstract The factors involved in the pathogenesis of
Crohn’s disease and ulcerative colitis, the two major types
of inflammatory bowel disease (IBD) are summarized.
Intestinal antigens composed of bacterial flora along with
antigen presentation and impaired mucosal barrier have an
important role in the initiation of IBD. The bacterial
community may be modified by the use of antibiotics and
probiotics. The dentritic cells recognize the antigens by cell
surface Toll like receptor and the cytoplasmic CARD/NOD
system. The balance between Th1/Th2/Th17 cell popula-
tions being the source of a variety of cytokines regulates the
inflammatory mechanisms and the clearance of microbes.
The intracellular killing and digestion, including autophagy,
are important in the protection against microbes and their
toxins. The homing process determines the location and
distribution of the immune cells along the gut. All these
players are potential targets of pharmacological manipu-
lation of disease status.
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APC antigen presenting cell
ATG16L1 autophagy-related protein 16–1
CARD caspase recruitment domain-containing protein
CD Chron’s disease
CD cluster of differentiation
CDAI crohn’s disease activity index
CpG cytosine—phosphate—guanine
DC dendritic cell
DSS dextran sulphate sodium
Ebi Epstein-Barr virus induced gene
GALT gut associated lymphoid tissue
G-CSF granulocyte colony stimulating factor
IBD inflammatory bowel disease
ICAM intercellular adhesion molecule




IRGM immunity-related GTPase family M
KGF keratinocyte growth factor
KSR Ras-1 kinase suppressor
LFA lymphocyte function-associated antigen
LPS lipopolysaccharide
MHC major histocompatibility complex
MMP matrix metalloprotease
NADPH nicotinamide adenine dinucleotide phosphate
NCF4 neutrophil cytosol factor
NF nuclear factor
NKT natural killer T cell
NLR NOD type receptor
NOD nucleotide-binding oligomerization domain
protein
PAMP pathogen associated molecular pattern
PAR proteinase activated receptor
L. Bene
Department of Internal Medicine, Peterfy Hospital,
Budapest, Hungary
A. Falus :N. Baffy :A. K. Fulop
Department of Genetics, Cell and Immunobiology,
Semmelweis University,
Budapest POB 370 H-1445, Hungary
A. Falus (*)
Research Group for Inflammation Biology and Immunogenomics
of Hungarian Academy of Sciences, Semmelweis University,
Budapest, Hungary
e-mail: faland@dgci.sote.hu
Pathol. Oncol. Res. (2011) 17:463–472
DOI 10.1007/s12253-011-9397-4
PPAR peroxisome proliferator activated receptor
PRR pattern recognition receptor
RAG recombination-activating gene
Ras rat sarcoma oncogene
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Against Decapentaplegic) protein
SOCS suppressor of cytokine signaling
STAT signal transducers and activators of transcription




TNF tumor necrosis factor
TNFR TNF receptor
TRC T cell receptor
UC ulcerative colitis
VCAM vascular cell adhesion molecule
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the two
primary forms of inflammatory bowel disease (IBD). These
diseases share many symptoms but in CD, the location of the
inflammation may occur anywhere along the digestive tract
from the mouth to the anus. In UC, the large intestine (colon)
is typically affected; however in some patients the small
intestinal ileum also shows the sign of inflammation [1].
Some detail of the relationship between the three items is
well known, however, the exact role of the various factors
in Crohn’s disease and ulcerative colitis is not well
elucidated. In many cases, the two diseases are well
differentiated clinically and histologically, but in about
10% of the cases, the transition of the two entities,
considered by many as a reasonably separate sub-group,
manifests as undetermined colitis.
Immune System of the Intestinal Tract
The immune system of the intestinal wall (gut associated
lymphoid tissue: GALT) contains a substantial amount of
immune cells responsible for the maintenance of the homeo-
stasis. Due to its villous structure, the gut has a large surface
area, the size of a tennis court (260–300 m2), all in contact
with the outer environment. Intestinal epithelial cells (IECs)
and M-cells lining the gut, therefore have a large area of
direct contact with the lumen. Under physiological con-
ditions, the normal intestinal flora of the gut comprises a
large number of bacteria, more than the number of somatic
cells. There are about 500 species; aerobes and anaerobes
live in symbiosis with the host organism. The normal flora
protectively impacts the mucosal immune response. It helps
protect against pathogens, participates in the metabolism of
metabolically active short chain fatty acids, carbohydrates,
bile acids and vitamins, and it has an important role in
maintaining a balance of the immune system by contributing
to the development of a tolerant immune response [2]. The
balance of protective and aggressive bacteria seems to be
analogous with pro- and antinflammatory cytokine patterns
and T-cell sub-populations. The change in the composition
of normal flora adversely affects the integrity of the
epithelium and the immune protection of mucosa even
without the presence of pathogens. Meanwhile, the conse-
quential change in the cytokine composition further impairs
the balance. Today, intestinal flora can be investigated or
even the precise composition can be analyzed by molecular
biological methods; however due to its expensive nature it is
not available in routine clinical practice. But it is known that
99% of the bacterial mass comprises only 30–40 species [3].
Ulcerative colitis occurs in sections of the colon where
there are the largest numbers of intestinal bacteria. The
distal ileum contains 108–1010 bacteria/gram while the
colon contains 1011–1012 bacteria/gram, predominantly
consisting of aerobes: Bacteroides, Clostridium, Bifidobac-
teria [4]. Clinical experience, including antibiotic and
probiotic therapies, has shown that in animals grown in a
germ-free environment no inflammation similar to human
IBD occurred suggesting that normal commensal flora has a
vital role in bowel inflammation [5].
If IL-10 secreting CD4+ cells together with Th1 helper
cells that can cause colitis alone are experimentally
transferred into immunodeficient animals, no bowel inflam-
mation occurs due to the antinflammatory effects of IL-10
[6]. It is proposed that in IBD the balance between IL-10
and other cytokines is upset, like other proinflammatory
conditions. This can explain the positive effects of anti-
biotics or probiotics in cases of relapse, which alone is not
sufficient and rather “transitory” since the genetic back-
ground of the individual does not change and this
influences the immune processes as well.
The deficient interaction between bacterial flora and
mucosa may lead to an abnormal immune response,
inflammation of the intestines, UC and CD. Previous data
demonstrates that intestinal flora in IBD is different from a
“normal” one [7], but it should be noted that our knowledge
of what normal flora is needs to be improved in order to
elucidate this issue.
Significance of Immune Tolerance in IBD
The body does not respond with systemic reactions against
harmless bacteria and nutritional antigens. The expansion
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of so-called controlled inflammation is inhibited by CD4+
T-cells [8]. Processes include T-cell anergy and apoptosis as
well as central clone deletion. Additional suppressor
mechanisms include the release of T-cell induced inhibitory
cytokines: IL-10, TGF-β, IL-4 [9].
T-cell apoptosis has a critical role in immune homeosta-
sis. In normal mucosa there is a high rate of Fas-mediated
apoptosis in T-cells of the lamina propria. However, in both
CD and UC the level of apoptosis is found to be
significantly decreased [10]. In patients with CD the level
of Bcl-2 and Bcl-xl with anti-apoptotic activity is increased
in T-cells, while Bax protein stimulating apoptosis is
decreased resulting in slower apoptosis [11].
Many experimental and human data demonstrate that
inflammatory bowel disease is the consequence of the
lack of normal mucosal immune tolerance. In IBD the
ratio of antibodies produced against nutritional antigens
is elevated. In the absence of appropriate tolerance, the
usual luminal flora induces active, non-regulated immune
response. The immune cells of the intestinal wall loose
the capability to differentiate between potential patho-
gens and non-pathogenic bacterial environment. Oral
tolerance can be stimulated by food intake similarly to
that occurring in active immunization as in case of Sabin
drops [12]. This method was shown to be useful both in
the prevention and therapy of IBD [13, 14]. By local
application of trinitrobenzoic acid (TNBA) Crohn-like, IL-
12 mediated Th1 type colitis can be provoked in mice. In
this case, the preventive effect of antigen feeding could be
demonstrated [15]. This phenomenon could not be
similarly reproduced in humans, indicating that regarding
oral tolerance there is a fundamental difference between
animal and human colitis.
With this in mind several attempts have partially
succeeded in demonstrating the differences of oral tolerance
among patients with inflammatory bowel disease, their
relatives and the normal population [16]. Although various
theories exist regarding the pathomechanism of IBD, based
on animal models, researchers agree that the intake of the
appropriate antigen could attenuate the inflammatory
process. The best findings have been reported by Ilian at
al. [17]. Colon biopsy samples were taken from ten patients
with CD, prepared and administered as food. After sixteen
weeks, significant decrease in CDAI was observed,
furthermore the peripheral NKT cell ratio increased, serum
IL-4 and IL-10 levels were elevated demonstrating activa-
tion of the antinflammatory system.
A similar mechanism can be proposed for how pro-
biotics and prebiotics work in routine practice; positive
results are achieved by influencing oral tolerance. Benefi-
cial therapeutic effects described in animal and human
pouchitis look to be promising [18]. Nevertheless, results
are contradictory and there is reasonable doubt. One
explanation could be the lack of appropriate antigen, dose
and the duration of treatment.
Antigen Presentation at the Mucosal Barrier
Dendritic cells, significant elements of antigen presentation,
reside in the luminal surface of mucosa and perceive
antigens in the intestinal content via their dendrites. In IBD,
their number is increased compared to normal and
expression of MHCII and T-cell co-stimulation molecules
on their surface is enhanced. An increase in interferon-γ,
IL-12, IL-18 release from dendritic cells (IL-4, IL-13
remain unchanged) can be observed in a mice model
compared to healthy controls. There are also larger numbers
of dendritic type cells in the mucosa associated lymphoid
tissue of patients with CD [19].
The functional condition of the predominantly mye-
loid origin antigen presenting cells (monocytes and
macrophages) in lamina propria depends on their loca-
tion, maturity and the degree of inflammation [20]. In the
murine Peyer’s patch, two different populations of
dendritic cells (DC) are localized: in the subepithelial
dome myeloid and in the interfollicular regions lymphoid
ones [21]. If CD11+ dendritic cells are isolated from
normal human colon previously treated with a prebiotic
agent (VSL#3), increased IL-10 and decreased IL-12p40
production (i.e. the antinflammatory processes) will
dominate. At the same time, lipopolysaccharide stimulated
IL-12p40 production can be stopped by adding VSL#3
[22]. It is important that the commensal flora continues to
live in the dendritic cells of Peyer’s patches and mucosal
lymphoid foci, but from here it does not penetrate further
and cannot be obtained from the spleen. Further penetra-
tion is inhibited by an IgA response independent from T-
cell line [23].
Dendritic cells present intestinal antigens to naïve T-cells
of the secondary lymphoid system (Peyer’s patches and
mesenteric lymph nodes). If dendritic cells obtained from
peripheral lymph node, spleen and Peyer’s patches are co-
incubated with CD8+ T-cells, the markers indicating
activation will increase irrespective of the site of origin.
However, only dendritic cells from Peyer’s patches are able
to increase the expression of adhesion factors (integrin
α4β7) and enhance “homing” of T-cells (i.e. increasing the
probability of encountering with the antigen) [24]. These
observations demonstrate that dendritic cells have a
significant role not only in recognition of the antigen but
also in the intestinal migration of T-cells. Based on the
above, it is not surprising that dendritic cells have a key
role in oral tolerance. Experimental observations dictate
that provoking expansion of the dendritic cells results in
increase of tolerance.
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In addition to the theoretical approach, observations also
confirm the role of these cells in IBD. Experimental models
demonstrate changing of dendritic cells in inflammatory
conditions. For example in the CD45RBhi colitis model an
increase of CD134L+ dendritic cells was found in the
mucosal lymphoid tissue following pathogenic T-cell
transmission in RAG1−/− mouse [25]. There is much less
data available regarding human IBD. Bell et al. have found
CD40, CD80, CD83 and CD86 co-stimulator molecule
expression in CD11+ dendritic cells isolated from rectum
and colon histological samples from patients with CD.
These results correlate with previous immunohistological
observations [26].
Others described in CD an altered behavior of dendritic
cells and the lack of thymic stromal lymphopoietin
production stimulating their maturity [27]. The importance
of this topic is emphasized by the fact that dendritic cells
have a significant role in how the innate and adaptive
immune cells react with the external environment, the
maintenance of homeostasis, and the development of a
tolerant or eliminating immune response. Does the dendritic
cell, having several subtypes, function well in IBD or does
the erroneous function have more of a role in the
development of the disease? Answers to these questions
may open the way to new therapeutic alternatives.
The Role of Innate Immune System in Perception
of Antigen: NOD and Toll-like Receptors
Discovery of the antigen recognizing structures of the
innate immune system (PRR—pattern recognition receptor)
are significant advances of the last decade. These receptors
are expressed on various cell types and the elements of this
system represent the first line in the microbial-mucosal
interaction and this process fundamentally affects further
events [28].
Toll like receptors (TLRs) are sensors on the cellular
surface, following contact with antigens they initiate
proinflammatory cytokine expression through the NF-κB
system that is the link between innate and adaptive
immunity. Deficiency or malfunctioning of these sensors
may lead to loss of adequate control of inflammatory
processes leading to the development of IBD.
The 14 (human and mouse) TLRs are categorized into 5
main groups, but their number is expected to increase in the
future. Many studies have demonstrated increased TLR
expression in IBD mucosa compared with healthy controls
[29]. There is the most data regarding the first described
TLR4 expressed typically on the apical surface of the cells.
Nearly 50% of the intestinal flora comprises Gram-negative
bacteria. The main antigen of gram negative bacteria is a
lipopolysaccharide (LPS) that serves as a substrate for the
TLR4 receptor. Another molecule called MD-2 participates
in recognition of the antigen; the expression of this can
hardly be measured in the normal colon mucosa, while in
IBD it is significantly elevated. The increased expression of
TLR4, MD-2, TNF-α, interferon-γ observed in the
inflamed intestine is the result of over-response to the
bacterial lipopolysaccharide [30]. TLR4 expression is not
uniform in the small and large intestines, possibly because
of the differing bacterial flora [31].
The possible significance of TLR4 in IBD is explained
by its specific behavior regarding the bacterial flora. It is
the most sensitive receptor to LPS to an extent that this
feature if it can be experimentally transmitted into animals
and the decreased LPS signal can be restored [32].
Activation of TLR4 results in expression of NF-κB,
myd88 protein, MAP kinases, and nuclear receptor perox-
isome proliferator activated receptor gamma (PPAR-γ)
[33]. TLR2 is typically expressed in the proximal colon
and under experimental conditions chemically induced
colitis models. Immunohistochemical analysis of crysec-
tions showed a significant increase in TLR2 expression in
the terminal ileum of patients with inactive and active UC
against controls. In the same study significant upregulation
of TLR4 expression was found in the terminal ileum and
rectum of UC patients in remission and in the terminal
ileum of CD patients with active disease. CD14 expression
was up-regulated in the terminal ileum of CD patients in
remission and with active disease, in the cecum of UC
patients in remission and with active disease, and in rectum
of UC patients with active disease. Hence, dysregulation of
TLR2, TLR4, and CD14 expression in different parts of the
intestinal mucosa may be crucial in IBD pathogenesis [34].
The most recent findings emphasized the role of
lipopolysaccharide-binding protein and soluble CD14 in
CD [35]. Epidemiological data have indicated that occur-
rence of childhood infections is in inversely proportional to
the risk of developing CD [36]. In vitro and in vivo studies
can confirm that bacterial LPS and CpG DNA enhances
Th1 response via IL-12 produced by dendritic cells [37].
Expression of TLR3 was found to be lower in patients with
CD when compared with those with UC and healthy
controls [38]. TLRs are not only expressed in the intestinal
epithelium but also in macrophages of the lamina propria,
the intestinal myofibroblasts, and the endothelial cells of
capillaries indicating their key role in innate immunity. It is
likely that genetic polymorphisms of the TLR receptor
affect the sensitivity of response to the pathogenic flora.
The protein family of NOD system located in the cytosol
is the receptor of innate immunity similar to TLR, and
participates in the reaction between host and pathogens. It
is beyond doubt that the most exciting discovery of the
recent period has been identifying the role of NOD2/
CARD15 gene in IBD. The NOD2 protein has a significant
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part in the development of the inflammatory response
against bacterial proteins (LPS and heat shock proteins) and
its genotype is associated with seroreactivity to microbial
components in CD [39]. The bacterial antigen attached to
the Toll-like receptor on the surface of monocytes and
macrophages and the cytoplasmic NOD2 protein induces
the corresponding pro- and antinflammatory cytokines via
NF–κB [40]. So it is not surprising, that NF–κB genetic
variant is associated with extensive colitis in IBD patient
[41]. According to our current knowledge, the role of
NOD2/CARD gene is markedly different in CD and UC. In
the latter, no significant correlation has been found between
gene mutations and developing the diseases, while in CD
this is confirmed by many studies [42]. This observation is
in accord with previous studies that have shown that a
bacterial event (infection) may have an inductive role in the
development of CD more so than in ulcerative colitis.
NOD2 mutations occur more often in stenotic Crohn
patients [43, 44]. This discovery has brought about a
marked advancement in the investigation of the pathome-
chanism of UC. This is the first indication of the
significance of genetics and focused researchers attention
on the role of bacterial “crosstalk” in disease etiology.
Mutation occurs in the leucine-rich part of the NOD2
molecule. This area is responsible for recognition of a
muramyl-dipeptide, the smallest part of the peptidoglycan
maintaining its antigenic features [45, 46]. In Crohn colitis,
NOD2 expression of epithelial cells is increased compared
to normal [47]. Proinflammatory cytokines such as TNF-α
and IFN-γ are able to increase NOD2 expression. In vitro
studies have demonstrated higher NOD2 expression of
intestinal epithelial cells against anti-bacterial pathogens
such as Salmonella typhimurium [48].
CARD15/NOD2 mutations are neither necessary nor
sufficient for disease occurrence. This observation is in
accordance with the retained complex genetic model for CD,
where genetic risk factors contribute only to a small
proportion of the variance (CARD15/NOD2 mutations are
very rare in Asian or African populations). The risk of disease
may appear relatively high in the people with mutations on
two of the two chromosomes. This dosage effect is consistent
with a loss-of-function model, where the molecular defect of
the gene lowers its efficiency. This loss-of-function model
was confirmed by many data from several groups using in
vitro models of transiently transfected cell lines [44].
In contrast, the gain-of-function mutations of CARD15/
NOD2 was also proposed based on potentiation of NF-κB
activity and IL-1β processing in mouse model. CARD15/
NOD2 is able to activate IL1β via the caspase 1 pathway
confirms the proinflammatory properties of CARD15/
NOD2 [49].
NOD1 is specialized to the peptidoglycan-muramyl
tripeptide of Gram-negative bacteria.
Experiments demonstrate that in NOD1-deficient mouse
bacteria are not eliminated due to the lack of response
against them. NOD1 system has important role in the
elimination of enteroinvasive, Gram-negative bacteria, like
Shigella flexneri [50].
Intestinal expression of NOD proteins is the manifesta-
tion of the reaction against the bacterial environment. When
it is deficient, function bowel inflammation may develop,
so it is not surprising that NOD2 mutations can be detected
in some patients with CD.
NOD2 expression can be observed not only on immune
cells but also on Paneth-cells, justifying paying increased
attention to this subject [51]. Paneth-cells are located at the
base of Lieberkuhn crypts and have a special role in the
protection of epithelial surface by producing antimicrobial
molecules. This occurs in large numbers mainly in the
terminal section of the ileum. In NOD2 mutant mice,
Paneth-cells produce significantly less antimicrobial pep-
tides (cryptidins) and the protection against orally admin-
istered bacteria is decreased. This corresponds with the
observation that bacterial adherence in the terminal ileum of
patients with CD, which is associated with the lack of
adequate protective apparatus (defensins), is significantly
increased compared to the normal population. Antimicro-
bial activity of defensins and cathelicidins is required for
the protection of the integrity of normal mucosa. In the
small intestine, α-defensin of the Paneth-cell is able to
regulate microorganisms, while β-defensin and cathelicidin
may induce an inflammatory reaction [52] (Figs. 1 and 2).
Any defects or damage to the barrier allow intrusion of
bacterial antigens leading to chronic inflammation. Precise
understanding of the role of defensins may provide the key
to a new therapeutic method, which could be tested through
administration of probiotics.
Polarization of the Adaptive Immune Response:
Th1 / Th2
CD is characterized by Th1 dominance, while in UC is the
less typical excess of Th2 dominates [53].
Altered composition of T-cells present in the lamina
propria can be typical for CD, and UC versus healthy
controls. In CD, CD4+ CD45R0+ T-cells and CD68
positive macrophages dominate. CD4+ T-cells are predom-
inantly of the Th1 phenotype and produce TNF-α, IFN-γ
and IL-6 [54]. In UC, IL-5 dominates in the cytokine
profile and to a lesser extent IFN-γ, which is characteristic
of the Th2 phenotype [55]. T-cells (CD4+ or CD25+)
producing regulating antinflammatory cytokines against T-
cell production of Th1 and Th2 type proinflammatory
cytokines, and Th1 producing IL-10 and Th3 producing
TGF-β are found in the intestinal wall [56]. In CD T-cell
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activation may be a result of IL-12, IL-23 and IL-18
cytokines released from dendritic cells and macrophages by
encountering luminal antigens [57]. Interferon-γ produced
subsequent to initiation of the process makes it self-
maintaining through intracellular STAT1-4 and T-bet
proteins [58, 59]. In UC, one of the key inductive cytokines
may be IL-13. [60]. Expression of other cytokines and
proteins have been described, among them perhaps IL-27,
Ebi-3, p28 subunit should be mentioned; however the
exploration of novel signal pathways may also be predicted.
In addition to other mechanisms, the cytokine milieu is
also characterized by the excessive presence of anti-
apoptotic ones: IL-2, IL-6, IL-15, IL-17, and IL-18. During
anti-TNF-α treatment, it was observed that while infliximab
with strong apoptotic potential worked well, while etaner-
cept without such an effect failed. Apoptotic activity is also
important in other treatments used for IBD, such as the
immunosuppressive drugs azathioprine and sulfasalazine.
The success of anti-TNF-α treatment in UC may also be
due to the apoptotic activity or the modulation of IL-33/
ST2 system which plays an important role in IBD and
experimental colitis, and may represent a specific biomark-
er for active UC [61]. Upon introduction of infliximab, UC
was considered a contra-indication because the main effect
Fig. 1 The factors of antigen
presentation leading to inflam-
matory bowel disease syndrome.
Th: T helper cell, IgA: immu-
noglobulin A, PG: peptidogly-
cans, LPS: lipopolysaccharides,
CpG: CpG dinucleotides, TLR:
Toll like receptors, APC: antigen
presenting cell, NOD: nucleo-
tide binding domain
Fig. 2 The major regulatory
factors in the pathogenesis of
inflammatory bowel disease
(IBD). The arrows show the
enhancement and the blunt end
symbols represent the inhibition.
IL: interleukin, TGF: transform-
ing growth factor, MMPs: ma-
trix metalloproteinases
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of the active substance was considered to block Th1
released TNF-α. Experience with other active substances
(etanercept) and the success of Phase 2 studies in UC
focused researchers’ attention to a common dominant factor
in maintenance of chronic inflammation; the lack of
apoptosis, characteristic to both types of IBD.
The effects of intercellular cytokines develop through
intracellular messengers targeting transcription factors. One
of the intracellular signal transducers is the STAT system,
which plays role in the post receptor signaling of different
antinflammatory cytokines, activated by the IL-6 cytokine
family, IL-10, G-CFS, and hepatocyte growth factor [62].
This is significant because in IBD the endogenous inhibitor
(SOCS3) level is increased, reducing the efficiency of
antinflammatory cytokines and enhancing apoptosis resis-
tance [63]. Experimental data have shown that STAT3
deficiency leads to IL-10 functional disorder and severe
gastrointestinal inflammation.
TGF-β also has antinflammatory potential. Under exper-
imental conditions, its deficiency causes severe bowel
inflammation or death [64]. Signal transduction of TGF-β
is mediated by Smad 2 protein, and the level of its natural
inhibitor, Smad7, is increased in IBD which also has a
proinflammatory effect. This is the explanation for the
increased TGF-β levels in IBD but without antinflammatory
effects due to the lack of an adequate signal transducer [65].
Deficient innate immunity results in faulty T-cell
response; and in such conditions (chronic granulomatosis,
glycogen storage disorders, cyclic neutropenia and leuko-
cyte adhesion syndrome) “crohn”-like intestinal alterations
may be observed [66]. Therefore it is postulated that
stimulation of innate immunity may have therapeutic effect
in patients with CD.
Role of TH17 Cells
TH17 (CD4+) T-cell lineage has been is characterized by
the production of the cytokine IL-17 and the development
of which is promoted by IL-23 and suppressed by
transcription factors required for TH1 and TH2 cells [67,
68]. It now appears that IL-23 is unnecessary for the
initiation of Th17 differentiation but is required at a crucial
control point in the Th17 response. STAT3, which is
activated by IL-23, was shown to be essential in expansion
and/or maintenance of the Th17 response. [69]. In human
T-cells, IL-23, together with TGF-β, IL-1β and IL-6 were
shown to induce Th17 differentiation and expression of IL-
17A, IL-17F, the IL-23R and the transcription factor
RORγt which is required for Th17 differentiation [70].
IL-23 was shown to suppress expression of Foxp3 which
induces regulatory T-cell development IL-23 was shown to
suppress expression of Foxp3 which induces regulatory T-
cell development [71]. If Foxp3 is present in T-cells, it can
divert differentiation away from Th17 because it binds
RORγt and blocks its action. Since Foxp3+RORγt+ cells
are found in the gut associated lymphoid tissue, it has been
suggested that IL-23 acts on this intermediate cell,
suppressing Treg development and thereby promoting
Th17 development [72].
So the TH17 cell lineage commitment is driven by
TGF-β in the presence of proinflammatory cytokines,
whereas IL-23 seems to maintain TH17 cell populations
[73]. In addition to its ability to support the differentiation
of TH17 cells, IL-23 induces the secretion of IL-17 by
non-T-cells in an inflammatory environment, and both T-
cells and monocytes serve as sources of increased
expression in the mucosa of IBD patients. IL-17 may
induce antimicrobial peptides and may regulate tight
junction barrier formation [74].
The TH17 cells produce IL-17A, IL-17F and IL-22
besides other cytokines. Th17 cells are clearly capable of
inducing intestinal inflammation, it remains to be deter-
mined which Th17 cell effector cytokines actually mediate
the inflammatory response. One candidate for pathogenesis
by Th17 cells is IL-17F. Although IL-17A and IL-17F have
overlapping activities in some systems, there is evidence for
differential activities in the gut. [70]
Intracellular Digestion and Autophagy
The impared phagosomal functions may reduce the patho-
gen elimination and handling of commensal flora. An SNP
within the first intron of neutrophil cytosol factor 4 (NCF4/
p40Phox) is associated with enhanced susceptibility to CD.
The protein product of this gene is a cytosolic regulatory
component of the superoxide-producing phagocyte
NADPH-oxidase [75]. Functionally impaired phagosomes
are less effectively in the killing resulting prolonged
microbe elimination and immune activation [76].
The autophagy pathway plays role in protecting
mammalian cells against various the cytotoxic effect of
bacterial toxins [77]. Following pathogen infection,
autophagy could represent a primary attempt to re-
establish homeostasis together with apoptosis. The rele-
vance to IBD is highlighted by the recent discovery that an
SNP in the auto-phagocytic gene ATG16L1 is associated
with increased risk for Crohn’s disease [78, 79]. ATG16L1
is broadly expressed in the intestinal epithelium, APCs,
T- and B-cells and may be involved in the host response to
intracellular bacteria [75]. Another autophagy gene
IRGM, required for mycobacterial elimination, is also
associated with Crohn’s disease risk [80], and may have
an analogous role in the granulomatous response observed
in Crohn’s disease [81, 82].
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Not only intracellular digestion, but extracellular one by
matrix metalloproteases is also suggested factor and
potential differential diagnostic tools for IBDs [83].
Lymphocyte “Homing”
“Lymphocyte homing” phenomenon is worthy to note for
pathophysiological and therapeutic reasons. During an
immune reaction due to antigen stimulus, the sensitized
T-cell should move from the central immune organ to the
periphery, into the target organ. This is usually the gut,
but in case of extra-intestinal manifestations, alteration of
homing in the endothelium will determine the target
organ. After encounter with the antigen, (priming) return
of effector cells into the lamina propria (homing)
depends on the expression of adhesion molecules. In
IBD, the expression pattern of adhesion molecules
changes. On the surface of CD4+ T-cells β2 integrin
LFA1, α4β1 and α4β7 integrins are expressed, while on
the surface of the endothelial cell ICAM-1, VCAM-1 and
MadCAM-1 appear [84]. Both LFA1 and ICAM-1
expression is increased in IBD compared to healthy
control. Thus, modulation of expression of adhesion
molecules may inhibit the elements maintaining the
inflammation from reaching the lamina propria that may
have beneficial therapeutic effect [85]. The role of Peyer’s
patch derived dentritic cells in the regulation of T-cell
α4β7 integrin expression and lymphocyte homing was
discussed in the section about antigen presentation.
Conclusion
Based on the diverse and in part controversial experi-
mental observations and scientific publications, it is
difficult to draw conclusions regarding the pathomechan-
ism of IBD. Nevertheless, the significantly genetically
determined innate immunity seems to be of primary
importance in IBD, and in particular in Crohn’s disease.
Consequently, when there is damage to the communica-
tion between the intestinal flora and the immune system
locally uncontrolled inflammation is likely. Additionally,
genetic background determines the uncontrolled immune
reactions that function abnormally and thus are unable to
correct the deficiency. It is associated with the damage of
mucosal barrier, continuous, unlimited intrusion of
invasive strains into the deeper structures that maintain
chronic inflammation due to the immune response; at
this stage considered normal. It is hard to determine if
immunological imbalance is the cause or the outcome,
but knowing the “double-face” of the system it is likely
that both factors are present at the same time. The
condition that is well known is caused by the hyperac-
tivity of the sensitized system due to genetic predispo-
sition. The degree of self-correction is likely to be
genetically regulated as well. An example of how this
is likely, is the efficiency of probiotics in pouchitis
where administration of antigen/probiotics alone has
therapeutic effects. This observation calls attention to
another essential issue: is the alteration of the bacterial
environment in IBD a result of deficient function of the
immune system or does a change in the bacterial flora
(for unknown reasons) cause chronic, uncontrolled
inflammation in genetically sensitized animals. These
are unanswered questions, but with the increased rate of
research in this area the numbers of such questions will
more than likely decrease in future.
Up to now, several factors have been proposed to be
involved in the pathogenesis of IBD, including bacterial
antigens of the intestinal flora and anomalies of immune
regulation, phagocytosis, antigen presentation (Fig. 1) and
balance between the different T-cell subpopulations
(Fig. 2). The various manipulation of these factors by
chemotherapy or probiotics, may lead to the prevention and
therapy of this severe pathologic condition in the future.
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